Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast with teleconference, Q3'24

By Inderes11/7/2024, 9:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:00 - 04:43

Thank you and welcome, everyone, to the webcast for Ascelia Pharma AB's Q3 report for 2024. On this call, we will be making forward-looking statements. On today's call, we will start with recent key events and then head into our portfolio update before moving to financials and priorities ahead. After the presentation, we will open up for questions. At Ascelia Pharma AB, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. Orviglance is in the registration phase as we have successfully completed the pivotal Phase 3 clinical study, SPARKLE, and we are preparing the NDA submission. Orviglance has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million. Oncoral is ready to start Phase 2 in the treatment of gastric cancer, based on encouraging results in Phase 1 and a high level of unmet medical need. Ascelia Pharma AB is based in Malmö, Sweden and we are listed on NASDAQ Stockholm. Communications in Q3 were dominated by the rights issue that has now been completed. The rights issue was fully subscribed to 105 million Swedish kronor, and as part of this transaction, we repaid half of the convertible loan to Fenja Capital, so it is now at 7.5 million. Since the end of Q3, there have been a number of activities that we have reported. The phase three primary endpoint results from SPARKLE have been accepted as a cutting-edge or late-breaking oral presentation at the RSNA, which is the largest radiology conference in the world. SPARKLE results have also been presented as a late-breaking abstract at Kidney Week 2024, which is a large nephrology conference in the US. This is important as the target indication for Orviglance includes people with severe renal disease who regularly see a nephrologist to manage their kidney disease. We are pleased that Marianne Kock has been elected to the board of directors at Ascelia Pharma AB, which happened at an extraordinary general meeting on October 30th. Marianne Kock has extensive experience in the pharmaceutical industry and executive roles, including work in drug development, regulatory affairs, and commercialization. Yesterday, we announced the completion of the full study report for SPARKLE, which reinforces the successful outcome of the pivotal Phase 3 study. Andreas will talk about this in a few minutes. We're very excited about Orviglance, and here is why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million global market opportunity, and Orviglance is a first-in-class product targeting this and has orphan drug designation from the FDA. We have strong data from nine clinical studies, and manufacturing has been upscaled to commercial scale with robust Phase 3 data. Orviglance has now advanced to the regulatory phase, and we are preparing for an NDA submission. We are pursuing some important value creation opportunities with Orviglance. The first objective is a timely submission and approval of Orviglance with the optimal label. The key steps on the way are. Completion of the SPARKLE clinical study report in early Q4 is now in place, as announced last night. The next milestone is the conclusions from the Pre-submission meeting with the FDA, which is expected in Q1, and the submission of the formal NDA application to the FDA in the middle of next year. The second key objective is to progress Orviglance for commercialization. The key activities here are to continue to advance our launch readiness by ensuring manufacturing and supply chain is ready for launch, as well as working with medical experts including key opinion leaders, payers, patient advocacy groups, and other key stakeholders. The other part of that is entering into a commercialization partnership, which is also a process that we are continuing our efforts in. I'm very happy with the progress we are making in Ascelia Pharma AB and the efforts made by our team to ensure we will meet our objectives and create value for shareholders. We will now start the portfolio section of our presentation with Orviglance. And I'd like to hand over to Andreas to continue the presentation. Thank you. Magnus. Orviglance is a.

Andreas Norlin
04:43 - 11:59

First-in-class liver MRI contrast agent, which addresses a very specific unmet medical need for which there are no good alternatives available today. Treatment of liver cancer and liver metastases is an important challenge within oncology. Adequate visualization of liver tumors and metastases is critical for making the right treatment decisions. Contrast-enhanced MRI is the gold standard procedure for examining patients with suspected or known tumors or metastases. The most used contrast agents are all based on the heavy metal gadolinium. In patients with severe kidney impairment, use of gadolinium-based contrast agents has been associated with an increased risk of a very severe side effect called Nephrogenic Systemic Fibrosis (NSF), which may even have a lethal outcome. Both the European and US regulatory authorities have, for that reason, issued warnings for the use of gadolinium-based contrast agents in this group of patients. The consequence is that patients with impaired kidney function typically will get an MRI without contrast, resulting in liver images of suboptimal quality, with the risk that their cancer is not managed in the best possible way. We envision that Orviglance, which is based on manganese, will address this unmet medical need and in the future become an efficacious non-gadolinium contrast agent for liver MRI in patients with impaired kidney function. In May, we shared the positive results from the SPARKLE Phase 3 study. We found that Orviglance-enhanced liver MRIs were superior to unenhanced MRIs. All three readers of the images reported strong, statistically significant results. We also noted that the common side effects were related to the gastrointestinal tract, which aligns with findings from previous studies on Orviglance. We have now finished the full study report for SPARKLE, and I'd like to share some of the key data and conclusions. First, let's have a look at the primary endpoint. The enhancement of focal liver lesion visualization was assessed through two co-primary variables: border delineation and lesion contrast. These were rated on a scale of 1 to 4 by three independent readers, and the mean scores for each patient, aggregated across all readers, are displayed in these bar charts. In the upper panel are the border delineation, and in the lower panel, you can see the lesion contrast. The height of each bar indicates the percentage of all patients receiving that score. Blue bars represent unenhanced images. Imaging results. While orange bars show the combined evaluation of unenhanced and Orviglance-enhanced images, scores for unenhanced images predominantly range from 2.1 to 3. In contrast to the previous assessment, the combined evaluation revealed a shift towards scores of 3 to 4, clearly indicating improved lesion visualization with Orviglance. The statistical evaluation compared Orviglance-enhanced scores with unenhanced scores within patients, and the mean paired differences, along with their 95% confidence intervals, are presented here. Notably, all mean paired differences are positive, indicating that Orviglance MRI is superior to unenhanced images for visualizing focal liver lesions. The analysis yielded a p-value of less than 0.001 for both variables across all readers, underscoring the significant advantage of combined MRI. To further validate our findings, subgroup analyses were conducted, and in every subgroup combined MRI was preferred over unenhanced MRI. The study also included various secondary efficacy analyses and safety evaluations. The secondary endpoints aim to assess different aspects of Orviglance's performance, reinforcing the primary conclusion that Orviglance enhances lesion visualization. Lesion visualization. Among the secondary endpoints, we observed that Orviglance increased the detection of lesions, measured as the proportion of patients with at least one additional lesion identified compared to unenhanced. Additionally, Orviglance improved the ability to detect and measure smaller lesions, with the smallest lesion being on average two millimetres smaller with Orviglance compared to unenhanced imaging. The results from other secondary endpoints consistently demonstrate the superiority of Orviglance over unenhanced MRI, with no analysis favoring unenhanced MRI. These endpoints include a quantitative assessment of signal intensity in the images, recommendations for the next step in treatment, and reader confidence in detecting and localizing lesions. Importantly, the performance of Orviglance alone was similar to when both Orviglance-enhanced and Unenhanced images were evaluated together. The primary safety analysis indicated that no serious adverse drug reactions were observed, and more than 80% of reported reactions were mild and short-lived, primarily related to the gastrointestinal tract, including nausea, diarrhea, and vomiting. The safety results from this vulnerable patient population were consistent with previous studies. With SPARKLE, we have completed the clinical development. The comprehensive clinical program includes a total of 286 patients and healthy volunteers in nine clinical studies. Taken together, these studies have consistently demonstrated positive efficacy and safety of Orviglance, with the Phase 3 SPARKLE study confirming the superior visualization of focal liver lesions in the target population of patients with severe kidney impairment and an adverse event profile consistent with what was observed in the other studies. We are moving ahead with the submission of the marketing approval application, the NDA for Orviglance. We are on track to submit the NDA for Orviglance by mid-2025. Having completed the full study report for SPARKLE, we are now focusing on finalizing our pre-NDA interaction with the FDA by the first quarter of next year. This step is crucial for laying the groundwork for our NDA submission and review, ensuring alignment with the FDA and facilitating a smooth review process. After submission, we expect a standard ten-month review period from the FDA. So in summary, the strong results from the SPARKLE study show that Orviglance provides superior imaging compared to unenhanced MRI, allowing us to move forward into the registration phase of Orviglance. So now I will hand it over to Julie.

Julie Waras Brogren
12:01 - 19:04

Thank you, Andreas. The addressable market for Orviglance is valued at $800 million globally on an annual basis. The US represents almost half of this. This market opportunity for Orviglance addresses the unmet need in a well-defined patient population—cancer patients who require liver imaging and also have severely impaired kidney function. Our strategy for commercialization is to launch through partners. This strategy supports our ambition to secure the optimal balance between future revenues and investment required. Our focused, ambitious launch strategy and plans, built on advanced market insights, are in place to support this partnering strategy and the launch. As mentioned, the US represents the largest commercial opportunity alone. Our real-world data, i.e. Data from realized procedures in our target patient population show that every year, 100,000 abdominal imaging procedures are performed in 50,000 patients that fall under the black box warning for gadolinium contrast agents. This is about 4% of people with cancer undergoing abdominal imaging. The well-defined patient population with this clear unmet need also drives an attractive value and pricing opportunity. And we have received extensive input from market access and pricing experts, with whom we have tested various pricing levels and collected insights on the evidence required to support access and reimbursement. And we have investigated pricing and access benchmarks of other innovative diagnostic drugs in the US. 90% of healthcare professionals are concerned with issues related to gadolinium contrast agents, including the severe side effects associated with our target patient population. In fact, 16% of providers have experienced cases of NSF in patients exposed to gadolinium. These insights come from market research with 270 US healthcare professionals and answers from radiologists, nephrologists, and oncologists, and the insights confirm the concerns with gadolinium in clinical practice and the unmet need for Orviglance. When speaking to experts in radiology and nephrology. They confirm that an alternative to gadolinium for our target patient population would address concerns of today, with the potential to become a valuable addition to their clinical practice. In clinical practice. This need is indeed well-recognized. Physicians tell us that patients who need liver imaging and fall under the black box warning for Gadolinium today receive MRIs that balance the trade-off between being either without a contrast agent, i.e., an inferior image quality, or with half dose Gadolinium. These are around 80% of the patients or by being given a full dose of gadolinium. With the awareness that gadolinium is not recommended for these patients due to the black box warning. In addition, we are both excited and optimistic that almost all physicians tell us that they would like to use Orviglance when it is available on the market. Beyond the risk of NSF in kidney-impaired patients. Gadolinium is well known to be retained in the brain and other tissues in all patients, and scrutiny over the possible safety effects is a key concern of regulatory and medical bodies. It is also well known that Gadolinium is excreted in the kidneys via urine, and because it's difficult to remove from our sewage systems, it is discharged into the environment and into our drinking water. There's an urgency to find a viable alternative to the growing use of toxic gadolinium, an alternative that is not associated with these potential safety and environmental concerns for patients and for the environment. With Gadolinium, in short, the momentum is improving, and the industry is responding. Recent developments from major gadolinium manufacturers are focused on smaller doses of gadolinium and an early-stage injectable manganese-based contrast agent, which, unlike Orviglance, is not liver-specific. We are excited that we have a head start, and that Orviglance is expected to be a first-in-class to lead a future with less gadolinium and improved outcomes for our target patients. The go-to-market strategy for Orviglance is to launch with commercialization partners, and our dialogue with these potential partners is progressing. This supports our objective to secure the optimal balance between future revenues and investment required. The strategy also allows us to leverage commercial capabilities already established by a partner. The focus of Ascelia Pharma AB is to continue the dialogue with potential partners and reach an attractive agreement for the commercialization of Orviglance. We are also working to ensure that Orviglance and the partner are ready to launch. Upon approval. We are excited to announce that the headline data from SPARKLE, the Phase 3 study for Orviglance, has been accepted in the late-breaking or cutting-edge categories for key conferences. RSNA for radiology and Kidney Week for nephrology. Our efforts to publish SPARKLE data and build relationships in the medical community continue as we progress with the NDA submission and our commercialization efforts with partners. In summary, Orviglance addresses a well-defined unmet need and represents an attractive commercial opportunity. Our focus is to ensure that Orviglance is ready for launch with a partner, and our efforts to help patients and launch Orviglance are well recognized by experts and partners in the industry. And with this, I will hand over to Andreas to talk about Oncoral.

Andreas Norlin
19:06 - 21:37

Thank you, Julie. So, let's talk about Oncoral. The other asset in our development portfolio, Oncoral, is a daily tablet formulation of irinotecan, a well-established intravenous chemotherapeutic agent. A daily tablet or tablet formulation enables a frequent low dose dosing regimen that could offer potential advantages in both efficacy and safety compared to the infrequent, high dose intravenous administration used today. And we have completed a Phase 1 study, which demonstrated a promising safety profile and an uptake of the drug after oral dosing, consistent with a daily dosing concept. We are now planning to advance ONCORAL into clinical Phase 2. The objective is to generate clinical proof of efficacy data in metastatic gastric cancer in combination with LONSURF, another oral cancer treatment approved for gastric cancer. Animal data have demonstrated a synergistic effect of irinotecan when combined with LONSURF, which makes this combination very interesting. The planned phase two study is designed to examine ONCORAL plus LONSURF versus LONSURF alone, and will randomize approximately 100 patients. It involves a clinical collaboration with Taiho Oncology, the developer and marketer of LONSURF, who will provide clinical advice and LONSURF for the study. Irinotecan is a well-established chemotherapy with recognized anti-tumor effects in solid tumors. Our strategy is to initiate ONCORAL development in gastric cancer, currently a $3 billion market for these patients. There is a high unmet medical need for improving outcomes, and there is an opportunity for an orphan drug designation. We also see opportunities for developing ONCORAL in other solid tumor indications, where a daily dosing tablet formulation can demonstrate an attractive efficacy and safety profile. Irinotecan as an IV formulation is already approved for colorectal and pancreatic cancer, and additionally, irinotecan is clinically demonstrated and recognized in guidelines for other cancer types. So we are assessing these opportunities as part of our ongoing strategic planning for Oncoral. Back to Julie. Again.

Julie Waras Brogren
21:37 - 25:58

Thank you, Andreas. So, we are moving to financing. In September, we completed our rights issue financing with this rights issue. We raised the full maximum financing of 105 million Swedish krona before costs. A minimum of 70 million Swedish kronor had been secured through investment commitments and guarantees. None of these guarantee commitments were executed, and the guarantors were paid in cash. Of the full financing, 7.5 million Swedish krona of convertibles to Fenja Capital have been amortized as part of the rights issue. We also have the opportunity to raise proceeds of up to 70 million Swedish krona in April 2025, from potential execution of the warrant. Series twenty-one. The financing secures resources for completing our NDA submission to the FDA mid-next year, including the key milestones along the way. The proceeds will also be used to obtain a partnering agreement for the commercialization of Orviglance, and to ensure that Orviglance is ready for launch upon approval with the fully subscribed rights issue. We now have a cash runway to late 2025, well beyond the NDA submission. In Q3. Our operating results were the lowest, i.e., costs of 17.8 million kronor. Costs of 17.8 million kronor. This is a slightly increased loss compared to Q2 this year, driven by our costs for the NDA preparations at the end of September. This year, we had 96 million kronor in the bank, with the full financing in place as mentioned. Our cash runway extends to late 2025, well beyond the NDA submission in mid-2025. This runway excludes potential payments from a commercialization partner, as well as the potential financing from exercising the warrant series of up to 70 million Swedish kronor. It also excludes the repayment of the remaining 27.5 million in loans to Fennia. So, to wrap up for today, we have substantial value creation opportunities ahead for Orviglance and Ascelia Pharma AB. With Orviglance, we are bringing to market a first-in-class diagnostic drug, addressing an $800 million US market for patients with a high unmet need. We have two key objectives. One key objective is the timely submission and approval of Orviglance with the optimal label. The key steps along this path include the completion of the SPARKLE clinical study report, which was announced last night, and we are on track for the pre-submission meeting with the FDA, with conclusions available in Q1 2025. We plan to submit the NDA in the middle of next year, 2025. Our other key objective is to advance Orviglance towards commercialization for patients in need by entering into a partnering agreement and ensuring that both a partner and Orviglance are ready upon approval. All in all, the strong headline results from SPARKLE mark the completion of clinical development for Orviglance and reinforce our confidence in the regulatory and commercial path ahead for Orviglance. We look very much forward to executing on these opportunities ahead, both for Orviglance and for Ascelia Pharma AB into 2025 and beyond. With this, we have completed the presentation. So, back to the.

Operator
25:58 - 26:18

Wish to ask a question. Please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Johan Yunus from Redeye. Please go ahead.

Unknown 1
26:22 - 26:48

Thank you for taking our questions and congratulations on the progress made. And the first question then is to perhaps give a bit more detail on the process leading up to the pre-admission meetings. When can we expect specific dates for the next interaction with the FDA?

Andreas Norlin
26:50 - 27:29

So, you’re asking about the process for the pre-NDA meeting. Did I understand that correctly? Yes, yes, yes. So we are preparing for that. And we are expecting to have the feedback from that process and the meeting in Q1 next year, and that the information or outcome of that meeting will then guide us to the NDA submission in mid 2025. So we are in the midst of preparing this. It's a quite lengthy process to get everything right. And it's very important that we do it diligently.

Unknown 1
27:33 - 27:45

Great. And this will be by the end of Q1. That will also include the minutes from the meetings. Just for clarification as well. Yes.

Andreas Norlin
27:45 - 27:50

So in Q1, we will have the final outcome minutes from the meeting. Yes.

Unknown 1
27:53 - 28:19

Yes. The OpEx run rate has been slightly higher due to, presumably, some external resources related to the NDA and the clinical protocol process. And should we expect some external resources also during the pre-submission meeting and during the time up to submission?

Andreas Norlin
28:20 - 28:39

So we are working with the external resources, CROs, that have the capacity to put everything together. It involves a great deal of documents and data that must be correctly organized. Uh, that is all included in our current budgets and covered in the runway.

Unknown 1
28:43 - 28:57

Yeah. So, is the recent quarter a good indication of what the range could be during this period in 2025, or are there slight variations?

Julie Waras Brogren
28:58 - 29:24

Um, yes. We haven’t specified the timing of the cost. But as Andreas said, the resources we need for the NDA submission and beyond, extending to late next year, are included in the current runway. And as you saw, we had these 96 million at the end of September. So we haven't specified beyond that.

Unknown 1
29:28 - 30:03

Yeah. And on the secondary endpoints, which is new as of yesterday evening. That clarification looks positive. Is it possible to put that in context, like the mean size of the smallest lesion was 2 millimeters smaller with Orviglance? What was the comparison with the average size of the smallest lesion? Is it possible to give that sort of granularity to the results?

Andreas Norlin
30:03 - 30:27

Yeah, I don't have the exact numbers in front of me, but as I recall, the mean size for the unenhanced was around 17 or 20mm. And then, with Orviglance, it's a little bit smaller than that. So two millimeters smaller. So that's. Yeah. The way. Yeah. Sorry.

Unknown 1
30:27 - 30:59

And in the. No, no, that's useful. Um, so approximately in that sort of range, and also in terms of detections of new lesions that were not detected by unenhanced, is it possible to give a reference to what the true numbers were in terms of I suspect you wouldn't detect all lesions even with the enhanced contrast?

Andreas Norlin
31:00 - 31:27

Now, the study is designed to measure lesions, number of lesions, and detect ability. And of course we don't know the truth, but as we have communicated, in half of the patients, we could find at least one more lesion. So, the proportion of patients was around 40 to 52% across the readers in which we found more lesions.

Unknown 2
31:27 - 31:28

Yes.

Unknown 1
31:30 - 32:00

Yeah. That sounds good as well. And also, in terms of interaction with potential partners, presumably, these conferences are important. One of the conferences was held very recently, and another one is scheduled to take place in the near future. Is there something to be said about that? And, if possible, any sort of sense of the level of interest from potential partners.

Julie Waras Brogren
32:02 - 32:48

The partnering dialogues are progressing, and of course, the partnering agreement also involves getting to know each other. Some of them may be at the conferences, but I think it's a somewhat separate issue, or let's say, an independent process. When we are at conferences, we always seize the opportunity to meet people we know or those we have yet to meet, including physicians and other industry stakeholders. It's always valuable at key conferences, not least to be recognized for our science, which also creates good awareness for us.

Marianne Kock
32:52 - 32:52

Mm.

Unknown 1
32:53 - 33:11

That's useful. And of course, even if it's not possible to give any feedback on the numbers and stages of discussions, you can confirm that there are ongoing discussions and interest.

Magnus Corfitzen
33:13 - 33:14

Yeah. We can confirm that.

Unknown 2
33:14 - 33:15

Mhm.

Unknown 1
33:18 - 33:51

Yeah. And uh, final question from our part. It's useful to map out and provide more feedback on the market opportunity arising from this. Do you have a sense of the number of early adopter clinics, especially in the US market? Can you provide some sense on that side?

Magnus Corfitzen
33:53 - 34:36

No, I think that's probably not really a measure that we would share or track at this stage. Right. What we are focused on right now is getting the FDA through the process and making sure we have a strong commercialization partner that is able to drive the launch. I think those are really the key parameters. We have a good understanding of the market on a number of different parameters and with many stakeholders. That's in our launch roadmap, and we will be working with a partner on it. So, I think we are in really good shape. It's a lot of hard work ahead of us, and we're looking very much forward to those activities.

Unknown 1
34:40 - 35:08

Yes. And presumably the potential partner wants to be well in place and prepared for the launch at the time of the future approval. And if an approval comes in around mid-2026, for example, or maybe slightly later, it would presumably be beneficial for a partner to be in place by at least the later stages of 2025 to start. Line of thinking.

Magnus Corfitzen
35:10 - 35:48

Yeah. I mean, obviously even for a large partner, it would take some time to get ready for the launch. We don't have a specific perspective on the timing. I think we are in good shape, and obviously, having a good partnership is more important than simply getting one signed. Uh. Too early. So? I think the process is progressing well and, uh, we're having some dialogues that we think are very encouraging. As we say, we have a strategic objective to find a partner. And that is progressing as it should.

Unknown 2
35:52 - 35:52

Correct.

Unknown 1
35:52 - 35:55

Looking forward to 2025. Thank you. Yes.

Julie Waras Brogren
35:57 - 35:57

Thank you, John.

Operator
36:00 - 36:05

The next question comes from Ludvig Svensson from Carnegie Investment Bank. Please go ahead.

Unknown 3
36:09 - 36:33

Yeah. Hello. And thank you for taking my question. So, while I understand that you're targeting a patient population for whom a full dose of Gadolinium is not an option. Uh, it would still be interesting to hear if it's possible to put this data into context in terms of what would be expected for a gadolinium-based contrast agent. Both regarding the primary and secondary endpoints.

Unknown 2
36:35 - 36:37

So you are asking.

Andreas Norlin
36:37 - 36:49

You are asking if Orviglance is comparable to gadolinium-based contrast agents in terms of image enhancement. Correct. And we have one study.

Unknown 3
36:49 - 36:49

In this setting.

Andreas Norlin
36:49 - 37:28

Setting. Yeah. We have one study. We have not used any comparator in the Phase 3 study. I think it's important to remember because it is a vulnerable patient population. So we don't have data from that patient population to compare with. But we have one study, one of the Phase 2 studies that included an arm of gadolinium-based contrast agents. And it's a smaller study. So, it still showed that the outcomes were comparable. So Orviglance is comparable to the multi-agents which were the comparator drugs in that Phase 2 study.

Unknown 3
37:32 - 37:46

Right. Perfect. And, um, you said that you expect a ten-month review time for Orviglance. Does this mean that you do not see priority review as an option, or have you received any indications from the FDA on this?

Unknown 2
37:47 - 37:48

We.

Andreas Norlin
37:48 - 38:03

Haven't. We conclude that the standard timeline is ten months. Uh, and it changes to that. We will communicate when we know more about it. But you're right. There is an option for priority.

Unknown 3
38:03 - 38:03

And.

Andreas Norlin
38:03 - 38:05

We have not excluded it. Yeah.

Unknown 2
38:06 - 38:07

Sorry.

Unknown 3
38:08 - 38:24

Yeah. All right. Makes sense. No problem. So, when negotiating a potential licensing deal with a partner, what would you say are your priorities in terms of deal economics? How important is the size of an upfront payment compared to a higher royalty rate? For example?

Unknown 2
38:27 - 38:28

Well, we.

Magnus Corfitzen
38:28 - 39:11

I think that’s, uh. I understand the question, but it’s not really possible for us to provide much detail. I think whenever you make a partnership, it's important that it's an attractive agreement for both parties. And if our partner is successful, they should be rewarded and we should be rewarded. So, I think that is really the balance we need to go for. And I'm sure we're going to find some way that is going to be good. And I think what would be fair would be to have a traditional transaction type with upfront milestones and royalties, and then we'll see how that structures. I know it will probably not help your modeling, but I think that's really all we can say now.

Unknown 3
39:15 - 39:19

All right. Great. And that was all from me. Thank you very much.

Marianne Kock
39:20 - 39:20

Thank you.

Operator
39:26 - 39:32

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad.

Magnus Corfitzen
39:37 - 39:52

Yes, we have received some questions here. Um, in the system here. We have one question regarding the European market and launching in Europe, concerning the steps involved and potential outcomes. Julie, do you want to take that one?

Marianne Kock
39:53 - 39:54

Yes.

Julie Waras Brogren
39:54 - 40:25

Uh, yeah. So, as we know, Europe has a separate regulatory process, but a large part of the filing and data from an FDA process is similar in Europe. In Europe, it's the same strategy to work with a partner; it may be the same one or perhaps someone else. And so, it's definitely part of our strategy. And we would like to make Orviglance available in as many markets as possible. European is the second largest market opportunity.

Marianne Kock
40:26 - 40:29

Um. Yeah. Yeah. Um.

Magnus Corfitzen
40:29 - 40:45

We have another question here. Um, asking for some more insights on our commercialization. You know, how we're thinking about commercialization partners and the process, and what type of partners and so forth.

Unknown 2
40:45 - 40:46

Um.

Magnus Corfitzen
40:46 - 40:49

And whether we're using an advisor or not.

Unknown 2
40:49 - 40:50

Yeah.

Julie Waras Brogren
40:50 - 42:18

Um, so, so one question here is what the process is and what kind of partners we're looking for. I think we talked about it. It's ongoing. We are fully prepared. Of course, we have a data room and so forth. In terms of types of partners, what is really attractive for Orviglance is that it could be valuable to many types of pharma companies. It could be someone who works in radiology, or it could also be someone who works in a related field. The most important aspect is that the partner promotes the product to hospitals. And also, it's a partner who has the capabilities to launch a product with high value. So it's a focused launch targeted at smaller patient groups where the efforts are really concentrated on market access and medical affairs. But many types of potential partners have these capabilities. Um, yeah. We haven't commented further on the process and whether we are using help. But of course, this is a key goal. So we are doing everything we can to make sure that we have the broadest possible outreach and we maintain a high-quality dialogue and process.

Marianne Kock
42:21 - 42:21

Mhm.

Magnus Corfitzen
42:23 - 42:40

Then we have another question about, um, you would say exclusivity for Orviglance. Um, and questions relating to the orphan drug market exclusivity of seven years from launch and something about 2040. Can you share some insight on that?

Julie Waras Brogren
42:40 - 43:44

Yes. So, Orviglance will be protected by the orphan drug designation. In the US, that is seven years from approval. This is a regulatory exclusivity for that specific patient population and label. The patent we have, extending to 2040, is for our second generation compound. So, an effervescent tablet that would otherwise have a similar profile or use as Orviglance. And this effervescent tablet is a very interesting opportunity for, for example, life cycle management of Orviglance. So, um, we have both of those things. So Orviglance will have seven years of exclusivity, and our second-generation patent extends to 2040.

Marianne Kock
43:45 - 43:45

Yes.

Andreas Norlin
43:46 - 43:47

Since 2020.

Marianne Kock
43:47 - 43:54

From 2020. Yes, yes. All right. There's more. Thank you.

Magnus Corfitzen
43:56 - 44:20

Well, thank you everyone for joining our Q3 quarterly report. Um, thank you for the questions and for the interest. We continue our efforts to move Orviglance forward, creating value in Ascelia Pharma AB and developing the company for the future. So thank you, and have a wonderful day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…